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This	  paper	  proposes	  the	  development	  of	  a	  drug	  product	  Manufacturing	  Classification	  System	  (MCS)	  
based	  on	  processing	   route	  and	  seeks	   feedback	   from	  the	  wider	  pharmaceutical	   science	  community	  
on	  the	  best	  way	  to	  apply	  it	  to	  practice.	  	  The	  MCS	  is	  intended	  as	  a	  tool	  for	  pharmaceutical	  scientists	  
to	  rank	  the	  feasibility	  of	  different	  processing	  routes	  for	  the	  manufacture	  of	  oral	  solid	  dosage	  forms,	  
based	   on	   selected	   properties	   of	   the	   Active	   Pharmaceutical	   Ingredient	   (API)	   and	   the	   needs	   of	   the	  
formulation.	  	   The	   proposed	   MCS	   could	   be	   used	   to	   develop	   a	   risk	   assessment	   for	   manufacturing	  
based	   on	   “ideal”	   ranges	   for	   API	   physical	   properties	   and	   therefore	   indicate	   how	   robust	   a	  
manufacturing	   process	   is	   likely	   to	   be	   in	   relation	   to	   those	   properties.	   The	   MCS	   will	   have	   many	  
applications	   in	  pharmaceutical	  development,	   in	  particular,	   it	  will	  provide	  a	  common	  understanding	  
of	  risk	  by	  defining	  what	  the	  “right	  particles”	  are	  (i.e.	  the	  physical	  properties	  of	  the	  particles	  that	  have	  
been	  identified	  for	  each	  process	  route),	  enable	  the	  selection	  of	  the	  best	  process,	  and	  aid	  subsequent	  
transfer	   to	   manufacturing.	  	   The	   ultimate	   aim	   is	   one	   of	   prediction	   of	   product	   developability	   and	  
processability	  based	  upon	  previous	  experience.	  	  Delivery	  of	   this	  goal	   requires	  sharing	  of	  data	   from	  
different	   sources	   to	   produce	  models	   of	   process	   robustness	   based	  on	  API	   physical	   properties.	   This	  
approach	  fits	  with	  Quality	  by	  Design	  (QbD)	  principles	  and	  has	  the	  potential	  of	  obtaining	  regulatory	  
relief	  on	  the	  development	  of	  dosage	  forms	  by	  demonstrating	  that	  the	  properties	  of	  the	  ingoing	  API	  
and	  excipients	  are	  within	  established	  ranges	  for	  the	  manufacturing	  process.	  Furthermore,	  this	  MCS	  
has	  potential	  to	  facilitate	  product	  development	  and	  reduce	  the	  incidence	  of	  late	  stage	  failure,	  thus	  
saving	  resource.	  
The	  four	  classes	  proposed	  are:	  	  
Class	  I:	  Direct	  Compression	  	  
Class	  II:	  Dry	  Granulation	  
Class	  III:	  Wet	  Granulation	  
Class	  IV:	  Other	  Technologies.	  	  
This	  proposal	  aims	  to	  provide	  a	  frame	  of	  reference	  for	  level	  of	  risk	  related	  to	  API	  physical	  properties	  
versus	  drug	  product	  manufacturing	  process	   type.	  	  Two	  concepts	   in	  particular	  have	  been	  expanded	  
upon:	  these	  being	  API	  developability	  and	  the	  impact	  of	  drug	  loading.	  	  The	  team	  has	  outlined	  the	  API	  
parameters	  and	  value	  ranges	  that	  define	  the	  recommended	  manufacturing	  class	  and	  the	  likelihood	  
of	  successfully	  developing	  an	  oral	  solid	  dosage	  form.	  	  As	  drug	  loading	  increases,	  API	  properties	  have	  
an	  increased	  influence	  on	  the	  formulation	  properties	  and	  processability.	  	  The	  team	  is	  proposing	  the	  
use	  of	  percolation	  (impact)	  levels,	  which	  may	  vary	  across	  different	  API	  attributes	  and	  parameters,	  to	  
quantify	  this	  risk.	  	  
This	   paper	   is	   intended	   to	   stimulate	   contribution	   from	   a	   broad	   range	   of	   stakeholders	   across	   the	  
pharmaceutical	  sciences	  to	  develop	  the	  MCS	  concept	  further	  and	  apply	  it	  to	  practice.	  	  	  In	  particular,	  
feedback	   is	  sought	  on	  what	  API	  properties	  are	   important	  when	  selecting	  or	  modifying	  materials	  to	  
enable	  an	  efficient	  pharmaceutical	  manufacturing	  process.	  	  	  	  Future	  work	  will	  build	  on	  ‘prior	  art’	  and	  
be	  a	  literature	  reference	  that	  can	  be	  used	  to	  articulate	  risk	  in	  a	  regulatory	  submission.	  
	  
	   	  
Advantages	  of	  a	  Manufacturing	  Classification	  System	  (MCS)	  
Processing	   of	   a	   pharmaceutical	   oral	   solid	   dosage	   form	   places	   great	   demands	   on	   the	   component	  
materials.	   	   They	  must	  mix	   readily	   into	   uniform	   blends,	   flow	  well,	   not	   adhere	   to	   surfaces,	   and	   be	  
compacted	   into	   tablets	   on	   high-­‐speed	   presses	   or	   encapsulated	   into	   capsules.	   	   	   Pharmaceutical	  
development	  rightly	  focuses	  on	  factors	  that	   impact	  the	  patient.	   	  Such	  factors	  were	  covered	  by	  the	  
development	   of	   the	   Biopharmaceutics	   Classification	   System	   (BCS)1.	   	   The	   BCS	   provides	   a	   scientific	  
framework	  for	  classifying	  drugs	  based	  on	  their	  solubility	  and	  intestinal	  permeability,	  in	  combination	  
with	  the	   in	  vitro	  dissolution	  characteristics	  of	  the	  drug	  product.	  	  These	  factors	  have	  been	  shown	  to	  
govern	  the	  rate	  and	  extent	  of	  oral	  drug	  absorption	  from	  solid	  oral-­‐dosage	  forms.	  However,	  the	  BCS	  
does	   not	   consider	   attributes	   beyond	   the	   solubility	   and	   permeability	   of	   the	   active	   pharmaceutical	  
ingredient	  (API).	   	  Many	  strategies	  for	  optimising	  exposure	  of	  poorly	  soluble	  drugs	  are	  now	  utilised2	  
but	  it	  is	  widely	  recognised	  that	  some	  of	  these	  strategies	  can	  make	  subsequent	  manufacture	  of	  drug	  
product	   challenging.	   	   A	   good	   example	   is	   particle	   size	   reduction,	   which	   may	   ensure	   optimum	  
exposure	  but	  may	  negatively	  impact	  flow	  and	  adhesion	  characteristics.	  	  There	  is	  therefore	  a	  need	  to	  
consider,	  within	  the	  constraints	  of	  BCS	  requirements,	  the	  selection	  of	  an	  appropriate	  manufacturing	  
technology	  and	  how	  API	  properties	   can	  be	  optimised	   to	   facilitate	  manufacturing	   requirements.	   	  A	  
Manufacturing	  Classification	  System	  (MCS)	  would	  facilitate	  this	  process.	  
Both	   the	   current	   costs	   of	   drug	   development	   and	   of	   product	   failure	   are	   extremely	   high	   as	  
development	   and	   manufacturing	   are	   highly	   resource	   intensive.	   	   Chemistry,	   manufacturing	   and	  
control	   (CMC)	   factors	  comprise	  a	  significant	  proportion	  of	   failures	  of	  NDA	  applications3.	   	   	   	  A	   lot	  of	  
knowledge	   currently	   exists	  with	   individuals	   and	   organisations	   based	   on	   their	   specific	   experiences,	  
but	   gathering	   this	   together	   in	   the	   framework	   of	   a	   MCS	   would	   provide	   guidance	   on	   the	   best	  
properties	   of	   a	   given	   API	   (molecular,	   particulate,	   surface	   and	   bulk)	   for	   a	   pharmaceutical	   process	  
route	   to	  enable	  manufacture	  of	   the	   finished	  drug	  product.	   	   	  For	  example,	   it	   is	  already	  known	  that	  
properties	  such	  as	  small	  particle	  size4,	   5	  and	  needle-­‐like	  morphology6,	   7	   can	   lead	   to	   issues	   like	  poor	  
flow8,	  difficulties	   in	  blending5,	  and	  unwanted	  adhesion9	   to	  surfaces	  such	  as	   tablet	  punches.	   	  These	  
issues	   can	   have	   the	   knock-­‐on	   effect	   of	   leading	   to	   failure	   of	   critical	   quality	   attributes	   of	   the	   final	  
dosage	   form	   e.g.	   tablet	   defects	   (picking,	   sticking,	   capping),	   dissolution,	   and	   content	   uniformity	  
failure.	   	   	  Managing	   this	   processing	   risk	   is	  made	  difficult	   by	   the	   fact	   that	  API	   properties	   frequently	  
change	   over	   the	   course	   of	   drug	   development	   due	   to	   modifications	   in	   synthesis	   route,	   planned	  
changes	   to	   more	   favourable	   polymorphic	   forms,	   downstream	   processing	   (intermediates	   to	   final	  
product)	  	  and	  scale-­‐up.	  	  	  
In	  summary,	  a	  MCS	  would	  aid	  product	  and	  process	  development	  and	  facilitate	  transfer	  to	  clinical	  and	  
commercial	   manufacturing	   facilities,	   whilst	   providing	   a	   common	   understanding	   of	   risk	   that	  
complements	   the	   BCS.	   	   There	   is	   a	   clear	   link	   between	   the	   MCS	   and	   BCS	   as	   the	   reproducible	  
production	  of	  a	  dosage	  form	  that	  does	  not	  impede	  dissolution	  and	  subsequent	  absorption	  is	  critical.	  	  
A	  further	  goal	  of	  a	  MCS	  would	  be	  the	  potential	  for	  obtaining	  regulatory	  relief	  on	  the	  development	  of	  
dosage	   forms	   by	   demonstrating	   that	   the	   properties	   of	   the	   ingoing	   API	   and	   excipients	   are	   within	  
established	  ranges	  suited	  to	  the	  specific	  manufacturing	  process.	  	  Examples	  of	  such	  regulatory	  relief	  
could	  include	  reduced	  end-­‐product	  testing	  or	  a	  streamlined	  approach	  to	  post-­‐approval	  changes.	  
This	   paper	   summarises	   discussions	   and	   conclusions	   from	   the	   APS	   conference	   “BCS	   to	   MCS:	  
Predictions	   From	   Material	   Science	   to	   Manufacturing”	   held	   in	   Nottingham	   in	   May	   2013	   and	  
subsequent	  discussion	  within	  APS	  focus	  groups	  and	  the	  MCS	  working	  party.	  	  It	  is	  published	  to	  invite	  
comments	  from	  the	  technical,	  scientific,	  and	  regulatory	  community.	  	  In	  particular,	  we	  are	  interested	  
in	   finding	   out:	   What	   API	   properties	   do	   you	   think	   are	   important	   when	   selecting	   or	   modifying	  
materials	   to	   enable	   an	   efficient	   pharmaceutical	   manufacturing	   process?	   Additional	   roundtable	  
discussions	  are	  planned	  for	  the	  UKPharmSci	  2014	  and	  FIP	  2015	  conferences.	  	  A	  final	  position	  paper	  
including	  comments	  on	  this	  article	  will	  be	  published	  after	  these	  sessions.	  	  
	  
MCS	  Based	  on	  Pharmaceutical	  Processing	  Routes	  
Traditionally,	  poor	  API	  properties	  can	  be	  overcome	  in	  two	  ways.	  	  Firstly,	  by	  the	  addition	  of	  functional	  
excipients	  specifically	  designed	  to	  aid	  processability.	  	  However,	  addition	  of	  excipients	  alone	  may	  not	  
be	  able	   to	  overcome	  unfavourable	  API	  properties	  particularly	  when	  there	   is	  a	  high	  drug	   loading	   in	  
the	   formulation.	   	   The	   second	   strategy	   is	   to	  granulate	   the	  material	   to	   form	  denser,	   larger	  particles	  
which	  are	  more	  amenable	  to	  processing.	  	  Delegates	  at	  an	  Academy	  of	  Pharmaceutical	  Sciences	  event	  
in	   Nottingham	   in	   May	   2013	   considered	   various	   outlines	   for	   a	   proposed	   MCS.	   	   Subsequently,	   a	  
decision	  was	  made	   to	  explore	  options	   towards	  developing	  an	  MCS	  based	  on	  processing	   route.	   	   	   It	  
was	   concluded	   that	   such	   a	   structured	   approach	   would	   assist	   formulators	   facing	   a	   common	  
challenge:	  how	  to	  rationally	  select	   the	  optimum	  processing	  route	   for	  a	  particular	  API.	   	   In	  addition,	  
such	   a	   MCS	   could	   assist	   in	   developing	   targets	   for	   designing	   optimised	   API	   that	   could	   then	   be	  
processed	  using	  a	  simpler	  processing	  route.	  	  	  We	  will	  now	  elaborate	  in	  greater	  detail	  on	  the	  different	  
processing	  routes	  intended	  to	  form	  the	  basis	  for	  a	  MCS.	  	  	  
A	  summary	  of	  three	  major	  conventional	  pharmaceutical	  solid	  oral	  dosage	  form	  processing	  routes	  is	  
given	   in	   Figure	   1a-­‐c.	   	   It	   is	   proposed	   that	   these	   three	   technologies,	   along	   with	   a	   fourth	   category	  
incorporating	  other	  technologies,	  form	  the	  basis	  of	  the	  MCS	  as	  follows:	  	  
1.	  Direct	  Compression	  (DC),	  	  	  	  
2.	  Dry	  Granulation	  (DG)	  	  
3.	  Wet	  Granulation	  (WG).	  	  	  
4.	  Other	  Technologies	  (OT)	  
This	  proposed	  MCS	  follows	  a	  similar	  philosophy	  to	  BCS,	  with	  the	  simplest	  manufacturing	  technology	  
(DC)	  occupying	   the	  Class	   I	   position.	   	  As	  highlighted	   in	   Figure	  1,	  moving	  down	   through	  Classes	  1-­‐3,	  
there	   is	   an	   increase	   in	   the	   number	   of	   processing	   steps,	   complexity	   and	   typically,	   greater	   costs	   of	  
manufacture10.	  	  The	  ability	  of	  the	  processes	  to	  accommodate	  unfavourable	  physical	  properties	  of	  the	  
API	  also	   increases	  as	  you	  move	  down	  through	  the	  classes.	   	  However,	   the	  API	  may	  be	  subjected	  to	  
greater	  stress	  during	  a	  more	  complex	  manufacture.	  	  These	  stresses	  include	  shear	  during	  milling	  and	  
roller	   compaction,	   exposure	   to	   moisture	   during	   wet	   granulation,	   and	   heating	   during	   drying	   and	  
coating.	  	  Such	  stresses	  are	  known	  to	  lead	  to	  changes	  to	  some	  API	  which	  can	  be	  problematic11-­‐16.	  	  An	  
additional	  complication	  is	  that	  multi-­‐step	  processes	  also	  make	  it	  more	  challenging	  to	  identify	  a	  root	  
cause	  for	  any	  problems	  that	  do	  occur.	  	  A	  fourth	  classification	  was	  proposed	  which	  would	  incorporate	  
more	  complex	  processing	  routes	  e.g.	  melt	  granulation,	  active	  coating	  and	  spray-­‐drying.	  
Drug	  Loading	  and	  Percolation	  Concept	  for	  Physical	  Properties	  
The	  higher	  the	  drug	  loading	  or	  level	  of	  an	  API,	  the	  more	  likely	  it	  is	  that	  the	  properties	  of	  the	  API	  will	  
impact	   the	  manufacturability/processability	   as	  well	   as	   the	  properties	   of	   the	   finished	  dosage	   form.	  	  
This	  can	  have	  a	  marked	  effect	  on	  the	  effort	  required	  to	  successfully	  formulate.	  	  The	  level	  at	  which	  an	  
API	   would	   impact	   the	   finished	   properties	   of	   the	   dosage	   form	   is	   referred	   to	   as	   the	   percolation	  
threshold.	  	  	  This	  threshold	  in	  turn	  would	  be	  influenced	  by	  whether	  the	  relevant	  property	  is	  a	  surface	  
or	  bulk	  (volume	  or	  mass)	  property	  of	  the	  API.	  	  
It	  may	  be	  assumed	   that	   the	  percolation	   threshold	   for	  bulk	  properties	  would	  change	  with	  differing	  
API	  properties	   such	  as	  particle	   size,	   shape,	   surface	  and	  mechanical	  properties.	   	  Hence	   it	  would	  be	  
expected	   that	   the	   percolation	   threshold	   for	   a	   given	   API	   would	   need	   to	   be	   confirmed	   from	   data	  
specific	   to	   that	   API.	   	   This	   threshold	   could	   be	   determined	   through	   data	   generation	   through	  
experimentation,	   computational	  modelling	  employing	  percolation	   theory	   tools17,	   or	   a	   combination	  
of	  both.	   	   	   	   Comparison	  with	  APIs	  of	   similar	  properties	   could	  also	  assist	   in	   this	  determination.	   	   For	  
example,	   blends	   containing	   micronised	   APIs	   will	   always	   have	   an	   increased	   risk	   of	   poor	   flow	   and	  
unwanted	  surface	  adhesion	  due	  to	   their	   small	  particle	  size	  /	  high	  surface	  area.	   	   	  From	  experience,	  
percolation	   thresholds	  would	   be	   low,	  with	   drug	   loadings	   higher	   than	   20%	   being	   expected	   to	   give	  
issues	   with	   all	   micronised	   materials	   in	   a	   DC	   or	   DG	   process.	   	   Ideally,	   to	   ensure	   robustness,	   the	  
formulation	   should	   be	   designed	   with	   an	   appropriate	   buffer	   zone	   away	   from	   the	   percolation	  
threshold.	   	   Values	   close	   to	   the	   threshold	  would	   run	   the	   risk	   of	   the	   formulation	  being	   sensitive	   to	  
changes	   in	   API	   particle	   properties.	   	   It	   is	   expected	   that	   the	   more	   the	   percolation	   threshold	   is	  
exceeded,	  then	  the	  stronger	  the	  impact	  of	  a	  given	  API	  property	  will	  be.	  	  Similarly,	  if	  parameters	  are	  
within	   the	   percolation	   threshold,	   the	   more	   robust	   the	   process	   is	   likely	   to	   be	   to	   accommodate	  
changes	   in	   API.	   	   It	   should	   be	   noted	   that	   the	   surface	   properties	   of	   some	   materials	   may	   have	   a	  
disproportionate	  impact	  compared	  to	  their	  bulk	  properties	  e.g.	  magnesium	  stearate.	  
Developability	  Concept	  
It	   is	   recognised	   that	   DC	   and	   DG	   can	   be	   regarded	   as	   part	   of	   the	   same	   continuum	   of	   increasing	  
densification	  and	  therefore	  there	  will	  be	  an	  overlap	  of	  the	  desired	  properties	  and	  varying	  degrees	  of	  
risk	   according	   to	   the	  manufacturing	   process.	   	  WG	  whether	   by	   low	   shear,	   high	   shear	   or	   top	   spray	  
methods	  involves	  more	  extensive	  modification	  of	  the	  API,	  but	  generally	  speaking	  the	  initial	  API	  and	  
particle	  properties	  are	  important	  factors	  influencing	  the	  process	  performance.	  	  The	  OT	  classification	  
by	   contrast,	   is	   reserved	   for	  materials	   that	   cannot	   be	   processed	   using	   the	   first	   three	   conventional	  
routes	   and,	   by	   its	   very	   nature,	   encompasses	   a	   wide	   range	   of	   potential	   technologies	   which	   are	  
described	  further	  in	  a	  separate	  section.	  	  This	  category	  recognises	  that	  the	  API	  properties	  need	  to	  be	  
so	  extensively	  modified	  by	  secondary	  processing	  that	   it	   is	  the	  properties	  of	  the	  final	  construct	  (API	  
alone	  or	  processed	  with	  excipient)	  that	  are	  critical.	  	  Indeed,	  the	  MCS	  may	  help	  to	  identify	  the	  desired	  
target	  properties	  of	  these	  constructs	  to	  allow	  subsequent	  processing	  using	  DC,	  DG	  or	  WG.	  	  	  	  	  
The	  concept	  of	  developability	  is	  introduced	  to	  assess	  how	  the	  physicochemical	  properties	  and	  dose	  
of	  the	  API	  aid	  or	  hinder	  the	  development	  of	  any	  dosage	  form.	  	  	  Table	  1	  summarises	  the	  properties	  of	  
an	  API	   considered	  desirable	   for	   a	  DC,	  DG	  or	  WG	  process.	   	   It	  would	  be	  unlikely	   that	   any	  molecule	  
would	  have	  all	  of	  these	  desired	  properties.	  	  However	  the	  further	  from	  these	  desired	  properties,	  the	  
more	  difficult	  and	  risky	  the	  development	  would	  become	  and	  the	  more	  detailed	  the	  control	  strategy	  
for	   manufacturing.	   	   References	   for	   these	   factors	   are	   given	   wherever	   possible.	   	   However,	   it	   is	  
important	  to	  note	  that	  some	  of	  the	  values	  cannot	  be	  sourced	  in	  the	  literature	  but	  represent	  current	  
best	  commercial	  practice.	  	  They	  are	  therefore	  intended	  as	  a	  starting	  point	  for	  discussion.	  	  Some	  may	  
not	   be	   applicable	   to	   all	   development	   and	  manufacturing	   indications	   and	   there	  may	   be	   additional	  
considerations	   specific	   to	   a	   particular	   API	   in	   a	   specific	   dosage	   form.	   	   The	   exact	   relevance	   of	   the	  
criteria	  would	  need	  to	  be	  risk-­‐assessed	  on	  an	  individual	  compound	  basis.	  
Future	  evolution	  of	  the	  MCS	  could	  involve	  subdividing	  the	  developability	  space	  into	  zones	  where	  DC,	  
DG	  and	  WG	  would	  be	  the	  preferred	  processing	  route.	  	  It	  is	  acknowledged	  that	  these	  zones	  might	  not	  
have	   sharp	   boundaries,	   with	   considerable	   overlap	   depending	   on	   the	   material	   property	   and	   the	  
nature	  of	  the	  API.	  In	  the	  following	  section	  developability	  parameters	  considered	  in	  the	  evolution	  of	  
the	  MCS	  are	  expanded	  upon.	  
Developability	  Parameters	  
Projected	  Dose:	   It	   is	   recognised	   that	   the	   toxicological	   risk	   is	   lower	   if	   the	  dose	   is	   less	   than	  50mg18.	  	  
This	  is	  independent	  of	  any	  percolation	  threshold	  considerations.	  	  When	  considering	  processability,	  it	  
should	  be	  noted	  that	  achieving	  content	  uniformity	  can	  be	  challenging	  for	  low	  doses	  less	  than	  1mg.	  	  
High	  doses	   can	  pose	  patient	  acceptability	   challenges	  due	   to	  difficulties	   in	   swallowing	   large	   tablets	  
with	  an	  upper	  weight	  limit	  for	  currently	  marketed	  products	  of	  approximately	  1.5g.	  	  	  
Particle	   Size:	  The	  D50:	   50µm	   -­‐	   500µm	   range	   is	   desired	   for	   tabletting.	   	   At	   lower	   sizes,	   electrostatic,	  
flow19	  and	  adhesion	  issues	  can	  be	  seen.	  	  At	  higher	  sizes,	  weight	  control	  of	  tablets	  and	  capsules	  can	  
be	   challenging.	   	   It	   is	   however	  possible	   to	  process	   lower	  particle	   sizes	  with	   appropriate	  processing	  
strategies.	  	  
Morphology:	  Needles	  and	  plates	  are	  more	   challenging;	   therefore	  an	  aspect	   ratio	   closer	   to	  1:1:1	   is	  
preferred20.	  	  Smoothness	  and	  roughness	  of	  surface	  are	  also	  factors	  especially	  at	  the	  extremes.	  	  Very	  
smooth	  particles	  for	  example	  could	  be	  challenging	  as	  they	  may	  remain	  separate	  from	  carriers	  which	  
could	  lead	  to	  content	  uniformity	  (CU)	  challenges.	  	  
Surface	  Area:	  As	  both	  particle	  size	  and	  shape	  are	  usually	   important	  surface	  area	  could	  be	  a	  useful	  
parameter	  that	  combines	  both	  particularly	  if	  surface	  chemistry	  effects	  are	  found	  to	  be	  important.	  	  
Form:	  A	  stable	  solid	  state	  form	  is	  needed	  because	  lack	  of	  form	  control	  (such	  as	  conversion	  to	  a	  more	  
stable	   polymorph)	   can	   lead	   to	   changes	   in	   material	   properties	   with	   associated	   manufacturing	  
challenges.	  	  This	  can	  in	  turn	  impact	  the	  desired	  final	  performance	  and	  stability21.	  	  	  An	  example	  of	  an	  
API	  with	  form	  issues	  is	  given	  under	  the	  Class	  4	  OT	  section.	  	  
Density:	   Density	   of	   API	   can	   also	   act	   as	   a	   descriptor	   for	   assessing	   suitability	   for	   manufacturing.	  
Various	  compendial	  methods	  exist	  for	  the	  measurement	  of	  true,	  bulk	  and	  tapped	  density22.	  	  Overall,	  
powder	   density	   parameters	   are	   useful	   for	   the	  derivation	  of	   compressibility,	   flow,	   and	   compaction	  
properties	  of	  powders.	  	  
Other	  parameters	  which	  can	  affect	  developability	  include:	  
Flow:	  	  Flow	  of	  particles	  is	  important.	  	  The	  Carr	  Index,	  or	  compressibility	  test,	  is	  one	  of	  the	  more	  easily	  
conducted	   tests,	   and	   is	   linked	   to	   recognised	  pharmacopeial	  definitions	   for	   flow	   (Figure	  2a).	   	  More	  
sophisticated	  tests	  by	  shear	  cell	  testing	  to	  measure	  flow	  functions,	  angles	  of	  internal	  friction	  or	  wall	  
friction	  can	  give	  more	  detailed	  analysis	  over	  a	  wider	  range	  of	  operating	  conditions	  (Figure	  2b).	  
Segregation:	   It	   is	  known	  that	  differences	  in	  particle	  size,	  shape,	  surface	  charge,	  cohesivity	  and	  bulk	  
density	  promote	  segregation.	  	  However,	  translating	  these	  values	  to	  quantify	  a	  risk	  of	  segregation	  is	  
difficult	  due	   to	   the	  multifactorial	  nature	  of	   these	   interactions.	   	   	   The	   impact	  of	  API	  particle	   size	  on	  
solid	   dosage	   form	   content	   uniformity	   can	   be	   assessed	   by	   a	   Monte	   Carlo	   style	   simulation23,	   24.	  	  
Similarly,	  for	  granulation,	  the	  impact	  of	  segregation	  on	  content	  uniformity	  can	  be	  assessed	  by	  means	  
of	  sieve	  assay	  methodology25.	  	  
Compression	   assessment:	   The	   tablettability	   (tensile	   strength	   versus	   compaction	   pressure)	   and	  
compactability	   (tensile	   strength	   versus	   solid	   fraction)	   of	   the	   finished	   granule	   or	   blend	   are	   key	  
outputs	  and	  dependent	  on	  the	  API,	  excipients	  and	  processing.	   	   	  As	  a	  general	  guide,	   	   if	   the	  finished	  
tablet	   has	   tensile	   strength	   of	   >1.7MPa	   at	   a	   solid	   fraction	   of	   <0.9,	   then	   the	   tablet	  will	   typically	   be	  
robust	  to	  further	  processing	  such	  as	  film	  coating,	  packaging,	  transport	  and	  handling	  by	  the	  patient26.	  	  
The	  expected	  solid	  fraction	  for	  a	  tablet	  is	  normally	  in	  the	  range	  0.85	  +/-­‐	  0.0527,	  28.	  	  Above	  this	  range,	  
there	  is	  increased	  risk	  of	  capping	  and	  lamination	  due	  to	  localised	  high	  density	  regions.	  	  	  Lower	  solid	  
fraction	   would	   not	   normally	   be	   an	   issue	   assuming	   that	   all	   the	   other	   tablet	   properties	   were	  
acceptable	  (e.g.	  friability).	  
More	   in-­‐depth	   analysis	   can	   examine	   and	   classify	   the	   properties	   of	   the	   API	   in	   terms	   of	   ductility,	  
brittleness,	   plasticity,	   elasticity,	   strain	   rate	   sensitivity	   etc.	   	   	   The	   generation	  of	   these	   values	   is	   very	  
much	   equipment-­‐	   and	   methodology-­‐dependent	   but	   such	   approaches	   can	   be	   useful	   in	   the	  
characterisation	   of	   API.	   	   An	   example	   of	   such	   an	   approach	   described	   by	   Roberts	   and	   Rowe29	   is	  
illustrated	  in	  Figure	  3.	  	  	  
Surface	   Adhesion:	   	   Surface	   adhesion	   values	   will	   change	   depending	   on	   the	   methodology	   of	  
determination.	  	  A	  number	  of	  differing	  approaches	  can	  be	  used:	  for	  example,	  direct	  measurement	  of	  
sticking	   forces	   such	   as	   ejection	   force,	   take	   off	   force,	   and	   adhesion	   punches	   via	   instrumented	  
presses/simulators.	   	   	   Alternatively,	   the	   adhered	  material	   can	   be	   analysed	   by	   visual	   observation30,	  
optical	   microscopy,	   scanning	   electron	   microscopy	   (SEM)	   or	   atomic	   force	   microscopy	   (AFM).	  	  
However,	  the	  values	  obtained	  from	  such	  experiments	  might	  not	  completely	  represent	  the	  behaviour	  
in	   dynamic	   environments,	   such	   as	   during	   flow,	  mixing	   etc.	   	   Other	   approaches	   include	  weight31	   or	  
assay32,	  33of	  powder.	  
Guiding	  Principles	  for	  Construction	  of	  a	  MCS	  
The	  aim	  of	  the	  proposed	  MCS	  is	  to	  set	  broad	  guidelines	  based	  on	  current	  knowledge	  using	  material	  
properties	  to	  classify	  manufacturing	  risk.	  	  	  It	  is	  not	  intended	  to	  be	  composed	  of	  hard	  rules,	  but	  rather	  
a	   guide	   to	   assess	   risk;	   based	   on	   the	   properties	   of	   the	   API,	   the	   intended	   dosage	   form	   and	   the	  
proposed	   manufacturing	   route.	   	   As	   progression	   is	   made	   down	   the	   first	   three	   categories,	   the	  
dependence	  on	  initial	  API	  properties	  is	  reduced	  reflecting	  the	  goal	  of	  the	  granulation	  process	  which	  
is	   to	  move	   the	  properties	  of	   the	  granule	  closer	   to	   the	  desired	  zone	  of	  developability	  properties	   in	  
Table	  1.	  	  	  
A	  key	  challenge	   is	  differentiating	  the	  API	  properties	   from	  the	  particle	  properties	  of	  the	  formulated	  
granule	   construct	   or	   particle	   and	   the	   resulting	   interactions	   with	   the	   manufacturing	   process.	   Any	  
classification	   system	   could	   become	   extremely	   complicated	   if	   the	   full	   range	   of	   properties	   and	  
potential	  interactions	  were	  to	  be	  considered.	  	  Its	  value	  and	  usage	  would	  be	  reduced	  if	  attempting	  to	  
factor	   in	   all	   actual	   and	   theoretical	   considerations.	   	   Instead,	   the	   aim	   is	   to	   develop	   an	   initial	  
classification	   scheme	   that	   is	   simple	   to	   understand	   and	   apply	   but	   still	   covers	   the	   most	   important	  
aspects.	  	  Once	  established,	  this	  MCS	  system	  can	  then	  be	  further	  developed.	  	  
Category	  1:	  Direct	  compression	  (DC)	  
DC	  uses	   two	  primary	  process	   steps	   (mixing	  and	  compression)	  and	   is	   considerably	   less	  complicated	  
than	  DG	  or	  WG	  (Figure	  1).	  	  However,	  it	  is	  likely	  to	  be	  the	  most	  reliant	  on	  initial	  API	  particle	  properties	  
for	  successful	  execution.	  	  A	  further	  challenge	  for	  DC	  is	  that	  not	  only	  should	  the	  API	  have	  acceptable	  
properties	  but	  these	  properties	  should	  be	  consistent.	  	  Mean	  particle	  size	  and	  distribution,	  together	  
with	   particle	   shape	   are	   particularly	   critical	   for	   direct	   compression.	   	   Unfavourable	   API	   particle	   size	  
and	  shape	  are	  bigger	  hurdles	  for	  DC	  formulations	  compared	  to	  granulation	  approaches	  as	  there	  is	  no	  
subsequent	   processing	   step	   to	   mitigate	   those	   unfavourable	   API	   properties.	   	   Table	   2	   outlines	   the	  
properties	   of	   an	   ideal	   DC	  material	   as	   proposed	   by	   Hancock	   in	   200434.	   	   Future	   work	   for	   the	  MCS	  
project	  initiative	  will	  involve	  updating	  these	  criteria	  in	  the	  light	  of	  recent	  knowledge.	  	  	  	  	  
Category	  2:	  Dry	  Granulation	  (DG)	  
DG	  (roller	  compaction	  or	  slugging)	  is	  usually	  regarded	  as	  more	  forgiving	  of	  input	  particle	  properties	  
than	  DC	  because	   it	  has	  an	  additional	  compression	  step	  where	  the	  API	   is	  granulated	  with	  the	  other	  
excipients	  by	  partial	  densification.	   	  Most	  of	   the	  desired	  properties	  of	   the	  API	   identified	   for	  DC	  are	  
also	   applicable	   to	   DG	   with	   the	   exception	   of	   properties	   associated	   with	   flow	   or	   bulk	   density.	  
However,	   the	   additional	   compression	   step	  may	   be	   disadvantageous	   for	  materials	  with	   potentially	  
limited	   compressibility.	   	   Therefore,	   the	   impact	   that	   partial	   densification	   has	   on	   the	   finished	  
tablettability	  of	  the	  formulation	  must	  be	  taken	  into	  account.	  	  Two	  approaches	  to	  risk	  assessment	  of	  
this	   effect	   are	   to	   determine	   how	  much	   the	   tablettability	   of	   the	   particle	   is	   reduced	   by	   DG,	   or	   to	  
ensure	   that	   the	   remaining	   tablettability	   is	   sufficient	   to	   form	   a	   robust	   tablet	   i.e.	   in	   excess	   of	   1.7	  
MPa24.	  	  	  Typically,	  it	  is	  found	  that	  the	  tensile	  strength	  of	  the	  ribbon	  or	  slug	  should	  be	  above	  1	  MPa	  to	  
ensure	  adequate	  mechanical	   strength	   for	  milling.	   	  DG	  may	  be	  better	   for	  elastic	  materials	   than	  DC	  
because	  DG	  utilises	  a	  slower	  compression	  process	  and	  can	  remove	  some	  of	  the	  elasticity	  (strain	  rate	  
sensitivity)	  allowing	  the	  resulting	  granules	  to	  behave	  better	  during	  tabletting	  compared	  to	  the	  initial	  
powder	   blend.	   	   	   Particle	   size	   of	   the	   input	   API	   must	   also	   be	   considered	   because	   it	   might	   impact	  
content	  uniformity.	  	  	  Likely	  factors	  to	  consider	  are	  listed	  in	  Table	  3.	  	  	  
Category	  3:	  Wet	  granulation	  (WG)	  
WG	   is	   a	  more	   complex	   process	   than	   either	   DC	   or	   DG	   but	   is	   able	   to	   handle	   a	  wider	   range	   of	   API	  
properties	   and	   transform	   the	   API	   into	   granules	   with	   superior	   properties	   in	   terms	   of	   downstream	  
processability.	  	  	  Given	  the	  wide	  range	  of	  process	  variables	  and	  complexity,	  the	  main	  wet	  granulation	  
method	  considered	  for	  the	  current	  benchmarking	  purpose	  will	  be	  high	  shear	  granulation	  due	  to	  the	  
ubiquity	   of	   its	   usage	   across	   the	   industry	   compared	   to	   other	   approaches	   such	   as	   Fluid	   Bed,	   Low	  
Shear,	  Hot	  Melt,	  Steam	  and	  Foam	  etc.	  	  	  	  
Another	   assumption	   is	   that	   the	   granulating	   liquid	   is	   water	   or	   water/co-­‐solvent.	   	   	   Applying	   the	  
concept	   of	   percolation	   threshold,	   some	   physical	   properties	   are	   strong	   drivers	   for	   or	   against	   wet	  
granulation.	   	  The	   list	   summarised	   in	  Table	  4	   is	  an	  example	  of	  what	  needs	   to	  be	   the	  basis	  of	  a	   risk	  
assessment,	  together	  with	  tentative	  ranges.	  	  	  	  
Category	  4:	  Other	  Technologies	  (OT)	  	  
OT	  refers	  to	  strategies	  needed	  for	  APIs	  that	  fall	  outside	  the	  developability	  criteria	  already	  outlined.	  	  
It	   is	   important	   to	   note	   that	   these	   strategies	   are	   purely	   those	   used	   to	   improve	  manufacturability.	  	  
Therefore,	   for	   example,	   strategies	   such	   as	   amorphous	   spray-­‐dried	   dispersions	   (SDDs)	   are	   not	  
covered	  if	  the	  primary	  intention	  of	  such	  a	  strategy	  is	  to	  improve	  bioavailability	  even	  if	  they	  have	  the	  
secondary	  effect	  of	  improving	  processability33.	  	  	  
This	  category	  necessarily	  covers	  a	  diverse	  range	  of	  technologies	  which	  is	  best	  illustrated	  by	  particular	  
examples	  and	  is	  not	  intended	  to	  be	  an	  exhaustive	  list.	  	  In	  this	  section,	  we	  have	  highlighted	  examples	  
of	   API	   properties	   which	   made	   them	   unsuitable	   for	   conventional	   manufacturing	   processes.	   	   Only	  
techniques	  which	  have	  been	  applied	  at	  a	  close-­‐to-­‐commercial	  scale	  will	  be	  described.	  	  	  
High-­‐drug	   load,	  moisture-­‐sensitive	  API:	  Melt	  granulation	   is	  a	  process	  where	  the	  API	   is	  subjected	  to	  
temperatures	  below	  that	  of	  its	  melting	  temperature	  but	  above	  the	  melting	  point	  or	  glass	  transition	  
temperature	  of	  the	  binder.	   	  One	  study	  described	  the	  evaluation	  of	  different	  processing	  techniques	  
for	  a	  poorly-­‐soluble	  oncology	  candidate35.	   	  As	  this	  API	  was	  moisture-­‐sensitive,	  wet	  granulation	  was	  
not	   feasible.	   	  Melt	  granulation	   improved	  granule	   flow	  properties	  with	   fewer	   fines	  and	  allowed	   for	  
higher	   drug	   loadings	   compared	   to	   DG.	   	   Other	   studies	   using	   imatinib36	   and	   metformin37	   achieved	  
satisfactory	  granule	  properties	  with	  drug	  loadings	  of	  up	  to	  90%.	  	  	  
API	  prone	   to	  degradation:	  Traditional	  processing	  of	   the	  peroxisome	  proliferator-­‐activated	   receptor	  
(PPAR)	  agonist	  peglitazar	  was	  not	  possible	  due	  to	  acid	  and	  base-­‐catalysed	  degradation38.	  	  An	  active	  
film-­‐coating	  approach	  was	  explored	  where	   the	  drug	  was	  added	  with	   the	   film-­‐coating	  material	  and	  
sprayed	  onto	   tablet	   cores.	   This	   approach	   yielded	   tablets	  with	   satisfactory	   chemical	   stability	  which	  
was	  attributed	  to	  the	  higher	  drug-­‐to-­‐excipient	  ratio	  in	  the	  film	  coat	  containing	  non-­‐reactive	  coating	  
materials,	  compared	  to	  that	  in	  the	  traditional	  DG	  or	  WG	  formulations.	  
Highly	  potent	  drugs:	  	  Highly	  potent	  drugs	  pose	  a	  safety	  challenge	  particularly	  when	  dealing	  with	  the	  
material	   in	   powder	   form.	   	   In	   addition,	   their	   associated	   low	   doses	   can	   pose	   a	   content	   uniformity	  
challenge.	   	  Modifications	   to	   the	  wet	   granulation	  process	  by	  dissolving	   the	  drug	   in	   the	   granulation	  
fluid	  can	  overcome	  this	   issue39.	   	   If	   this	   is	  not	   feasible	   then	   the	  Liquid	  Dispensing	  Technology	   (LDT)	  
method	  can	  be	  used	  where	  a	  solution	  of	  the	  drug	  is	  deposited	  on	  an	  inert	  tablet	  core40.	  	  
Form	  challenges	  :	  The	  HIV	  pharmacokinetic	  booster	  cobicistat	  is	  not	  isolated	  as	  the	  crystalline	  form	  
but	  as	  an	  amorphous,	  hygroscopic	  solid	  form	  of	  low	  glass	  transition	  temperature41.	  	  This	  form	  readily	  
transforms	  under	  ambient	  conditions	  via	  a	  moisture-­‐	  and	  temperature-­‐driven	  phase	  transformation	  
into	  a	   rubber-­‐like	  material	   that	   is	  difficult	   to	  process.	  Removal	  of	   the	  adsorbed	  moisture	  does	  not	  
lead	   to	   reversion	   to	   the	  original	   solid	   form.	   	  A	   free-­‐flowing	  powder	   is	  obtained	  by	  adsorbing	  onto	  
silica	  following	  evaporation	  from	  a	  dichloromethane	  solution	  as	  part	  of	  the	  API	  isolation.	  	  Although	  
still	   hygroscopic,	   moisture	   uptake	   is	   now	   reversible	   and	   it	   no	   longer	   undergoes	   phase	  
transformation.	  	  	  
Another	   common	   form	   issue	   involves	  API	  which	   is	   liquid	   at	   room	   temperature.	   	   In	   order	   to	  use	   a	  
standard	  manufacturing	  technique,	   large	  amounts	  of	  excipients	  may	  be	  needed	  to	  convert	  the	  API	  
into	  a	  suitable	  powder,	  which	  in	  turn	  can	  lead	  to	  an	  impractically	  large	  dosage	  form.	  	  Liquid	  or	  semi-­‐
solid	  filled	  capsules	  have	  been	  used	  	  for	  several	  commercial	  products	  	  such	  as	  fish	  oils	  and	  Vitamin	  E,	  
to	  overcome	  this	  challenge42.	  	  	  	  
	  
Graphical	  representation	  of	  risk	  
The	  aim	  of	  the	  MCS	  is	  to	  facilitate	  classification	  of	  risk	  with	  respect	  to	  key	  physical	  properties.	  	  One	  
approach	  to	  aid	  this	  is	  to	  represent	  risk	  graphically.	  	  As	  part	  of	  developing	  the	  concept,	  several	  such	  
approaches	  have	  been	  explored.	  	  Parallel	  coordinate	  plots	  (Figure	  4a)	  or	  spider	  plots	  (Figure	  4b)	  can	  
be	  used	  to	  view	  all	  the	  key	  physical	  properties	  holistically	  as	  well	  as	  score	  or	  rank	  these	  with	  respect	  
to	   extent	   of	  manufacturability	   risk.	   	   These	   provide	   a	   quick	   overview	   of	   the	   level	   of	   risk	   (i.e.	   how	  
much	   of	   the	   plot	   is	   in	   a	   high	   risk	   region)	   and	   also	   helps	   to	   identify	   the	   problematic	   physical	  
properties	  and	   likely	   failure	  modes.	   	  Alternatively,	  a	   risk	  analysis	  score	  can	  be	  calculated	  based	  on	  
relevant	  API	  attributes	  and	  drug	  product	  target	  attributes.	  	  The	  overall	  score	  can	  be	  used	  to	  identify	  
appropriate	  processing	  strategies	  (Figure	  4c).	  	  	  
Further	  work	  
This	   paper	   gives	   an	   outline	   of	   an	   MCS	   approach	   based	   on	   current	   knowledge	   available	   in	   the	  
literature.	  	  	  Further	  input	  is	  needed	  focussing	  on	  the	  following	  areas:	  
• More	   data	   on	   input	   API	   properties	   and	   resulting	   particulate	   and	   formulation	   properties	  
could	   be	   shared	   or	   generated	   through	   focused	   experiments	   to	   validate	   and	   assess	   the	  
advantages	  and	  limitations	  of	  the	  MCS.	  	  	  
• Additional	  data	  could	  also	  enable	  the	  subdivision	  of	  the	  developability	  space	  into	  zones	  best	  
represented	  by	  DC,	  DG	  and	  WG.	  	  	  
• Construction	  of	  Target	  Material	  Profiles	  would	  inform	  API	  optimisation,	  thus	  moving	  it	  from	  
one	  process	  zone	  to	  another.	  	  	  
• Surrogate	  materials	  could	  be	  identified	  which	  would	  represent	  the	  different	  process	  zones:	  	  
this	   would	   give	   flexibility	   as	   each	   individual	   organisation	   could	   use	   these	  materials	   to	   set	  
their	  own	  favoured	  parameters	  using	  their	  own	  characterisation	  techniques.	  	  
• Ideally	   the	  work	   should	   be	   extended	   to	   exploit	  modelling	   tools	   for	   predicting	   formulation	  
and	   manufacturing	   outcomes	   starting	   with	   molecular	   structure,	   intrinsic	   and	   behavioural	  
material	  properties.	  	  	  
The	  challenge	  for	  these	  future	  efforts	  will	  be	  to	  strike	  a	  balance	  between	  a	  system	  which	  is	  simple	  
enough	  to	  apply	  whilst	  still	  capturing	  all	  the	  important	  factors.	  	  	  	  
	  
Summary	  
In	  this	  paper,	  a	  proposal	  is	  made	  to	  develop	  a	  MCS.	  	  It	  is	  further	  proposed	  to	  identify	  the	  likely	  key	  
parameters	   of	   a	   MCS	   with	   a	   suggestion	   of	   potential	   values.	   The	   concepts	   of	   developability	   and	  
percolation	   threshold	   have	   been	   introduced	   with	   parameters	   defined.	   	   These	   values	   would	   be	  
expected	   to	  vary	  with	   the	   individual	  API	  and	   formulation	  and	  would	  be	  assessed	  by	  a	   risk	  analysis	  
approach.	  	  No	  single	  approach	  would	  be	  expected	  to	  be	  best	  for	  all	  situations,	  but	  a	  framework	  has	  
been	   created	   detailing	   the	   key	   factors	   to	   be	   considered	   in	   risk-­‐assessing	   the	   development	   of	   a	  
compound	  and	   its	   interactions	  with	  a	  manufacturing	  route.	   	  This	  tool	   is	  meant	  to	  complement	  the	  
application	   of	   QbD	   by	   assisting	   with	   the	   rational	   selection	   of	   manufacturing	   processes	   for	   drug	  
product.	   	  Further	  work	  and	  sharing	  of	  data	  are	  needed	  to	  provide	  greater	  detail	  and	  confidence	   in	  
this	   proposal.	   	   We	   encourage	   input	   from	   interested	   parties	   on	   how	   to	   improve	   and	   apply	   this	  
paradigm	   in	   particular	   to	   detail	   the	   API	   properties	   they	   feel	   are	   important	   when	   selecting	   or	  
modifying	  API	  to	  enable	  drug	  product	  manufacture.	  
	  
Acknowledgements	  
The	  authors	  would	  like	  to	  thank	  Linda	  Hakes	  and	  Bruno	  Hancock	  for	  their	  helpful	  comments.	  	  
	   	  
Tables	  
Table	  1:	  Desired	  properties	  of	  an	  API	  for	  consideration	  as	  a	  DC,	  DG	  or	  WG	  solid	  dosage	  
form	  
Property	   Value	   Source	  
Melting	  Point	   >	  900C	   Ibuprofen	  Mpt	  76	  0C43	  
Contact	  angle	  Water	   <	  900	   Usual	  accepted	  point	  of	  wetting	  
Moisture	  uptake	   <1%	  weight	  change	  over	  manufacturing	  
humidity	  and	  temp	  range	  
Idealised	  
Dose	  number	   <250mL	   BCS	  classification	  system	  
Bulk	  density	   >0.3g/mL	  (equivalent	  to	  0.21	  solid	  
fraction	  of	  a	  1.4g/mL	  true	  density	  
material).	  
Manufacturing	  Efficiency	  
Stability	  /	  Compatibility	   >	  2years	  at	  room	  temp.	  	  Compatibility	  
with	  common	  pharmaceutical	  
excipients.	  
Idealised	  
Particle	  size	   50	  to	  500	  microns	   Idealised	  
Morphology	   Aspect	  ratio	  1:1:1	   Idealised	  
Form	   Stable	  under	  standard	  manufacturing	  
environmental	  conditions	  
Idealised	  
	   	  
	  
	   	  
Table	  2:	  Properties	  of	  an	  Ideal	  Direct-­‐Compression	  Material	  	  	  
Adapted	  from	  McCormick	  200534	  from	  a	  talk	  given	  by	  BC	  Hancock	  “Identifying	  candidates	  for	  
direct	  compression	  using	  material-­‐sparing	  formulation	  tools”	  presented	  at	  AAPS	  November	  2004.	  	  
Property	   Value	   Target	  Value	  
Particle	  Size	  and	  Shape	   D	  4,3	  (mean	  volume	  diameter)	   >	  80µm	  
	   D	  10	  (10th	  percentile	  diameter)	  
D	  90	  (90th	  percentile	  diameter)	  
Aspect	  Ratio	  
>	  30µm	  
≤	  1000	  µm	  
<	  1.5	  
Blend	  Uniformity	   Blend	  Potency	   <2%	  relative	  standard	  deviation	  
Powder	  Flow	   Effective	  angle	  of	  internal	  
friction	  
<	  41°	  
Powder	  density	   True	   1.0	  -­‐	  2.5	  g/mL	  
Bulk	   >	  0.5	  g/mL	  
Tableting	  performance	   Dwell	  time	  sensitivity	   Low	  
	   Precompression	  force	   Low	  
	   Compression	  stress	  	  
(at	  	  ~	  0.85	  solid	  fraction)	  
20	  -­‐	  125	  MPa	  
Compact	  mechanical	  properties	   Tensile	  strength	  	   >	  1.0	  MPa	  
(at	  	  ~	  0.85	  solid	  fraction)	   Brittle	  fracture	  index	  	   <	  0.2	  
	   Indentation	  hardness	  	   75	  -­‐	  250	  MPa	  
	  
Table	  3:	  Properties	  of	  an	  Ideal	  Roller	  Compaction	  Material	  
Property	   Value	   Target	  Value	  
Compactability	   At	  0.7	  solid	  fraction	   >1MPa	  
Loss	  of	  compressibility	   Compressibility	  remaining	  in	  granules	   >1.7MPa	  
Bulk	  density	   At	  >	  0.14	  solid	  fraction	   >0.2g	  per	  mL	  
Too	  low	  friction	  (no	  grip)	   Angle	  of	  wall	  friction	   <20	  degrees	  
Flow	  assessment	  
	  
Solid	  State	  Properties	  




Melting	  point	   >90	  0C	  
	   Glass	  Transition	  (Tg)	   >90	  0C	  
	   Loss	  of	  crystallinity	  during	  compaction	   None	  
Particle	  size	  for	  CU	   Blend	  potency	   Meets	  Rohr’s	  criteria23	  




	   	   	  	  
	  
	  
Table	  4:	  Key	  Considerations	  for	  Selection	  of	  Wet	  Granulation	  
Colours	  denote	  level	  of	  risk	  factor.	  
Property	   Condition	   Drug	  Loading	   Comment	  
	   	   Low	   Medium	   High	   	  














Wet	  gran	  may	  improve	  
dissolution	  rate	  and	  
manufacturability	  
	  
Moisture	  Sensitivity	   	   H	   H	   H	   High	  Risk	  
	  
Morphology	   Plates	   L	   M/H	   H	   Can	  have	  capping	  
problems:	  May	  need	  to	  
mill	  /	  recrystallise	  API	  
	   Needles	   L	   H	   H	  
	   Equant	   L	   L	   L	   	  
Deformation	  
Mechanism	  
Elastic	   L	   L/M	   M/H	   The	  greater	  the	  elastic	  
component	  the	  higher	  
the	  risk:	  May	  need	  to	  mill	  
/	  recrystallise	  API	  
	   Plastic	   L	   L	   L	  
	   Brittle	   L	   L	   L	  
Solubility	  Interaction	   Binder	  Interaction	  
Aids	  Release	  
L	   L	   L	   	  
	   Binder	  Interaction	  
Slows	  Release	  
L/M	   M	   H	   	  
Polymorph	  /	  Hydrate	  
Formation	  
	   M/H	   M/H	   M/H	   Polymorphic	  changes	  
due	  to	  the	  presence	  of	  
solvent	  
Melting	  Range	   <	  90°C	   L	   L/M	   M/H	   	  
	   >	  90°C	   L	   L	   L	   	  









High	  tendency	  to	  
segregate	  



























	  Figure	  1c	  
Figure	  1:	  Schematics	  of	  (a)	  Direct	  Compression	  (b)	  Dry	  Granulation	  (c)	  Wet	  Granulation	  
Processes	  
	   	  
	  	  
	  
Figure	  2	  (a)	  USP	  monograph	  values	  for	  Carr’s	  Index45	  (b)	  Flow	  Function	  Table46	  
	  
	   	  
1-­‐2	  Very	  cohesive	   	  2-­‐4	  Cohesive	   4-­‐10	  Easy	  Flowing	   >10	  Free	  Flowing	  
	  	  
Figure	  3:	  Compaction	  Classification	  by	  Material	  Properties	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  Figure	  4(c)	  
	  
Figure	  4:	  Tools	  to	  Visualise	  Risk	  in	  Respect	  of	  Different	  Properties	  (a)	  Parallel	  Co-­‐ordinates	  
Charts	  (b)	  Spider	  Plots	  (c)	  Risk	  Analysis.*	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